Sistema de Salut de Catalunya
Institut Català de la Salut
[Schettini F] Translational Genomics and Targeted Therapies in Solid Tumors Research Group, Barcelona, Spain. Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. [Giuliano M] Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. [Lambertini M] Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy. Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. [Bartsch R] Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria. [Pinato DJ] Division of Cancer, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK. Department of Translational Medicine, Università del Piemonte Orientale “A. Avogadro”, Novara, Italy. [Onesti CE] Clinical and Oncological Research Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Cortes J] Oncology Department, IOB Institute of Oncology, Quiron Group, 08023 Madrid, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-03-15T12:24:22Z
2022-03-15T12:24:22Z
2021-09
Antraciclines; Càncer de mama; Receptor hormonal
Antraciclinas; Cáncer de mama; Receptor hormonal
Anthracyclines; Breast cancer; Hormone receptor
Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450–480 mg/m2. Following three pivotal first-line phase III trials in HER2-negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2-negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms.
This study was supported by Mednote, spin-off—University of Trieste, within the Mozart Program.
Article
Published version
English
Mama - Càncer - Tractament; Quimioteràpia combinada; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols; Other subheadings::Other subheadings::/therapeutic use; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada; Otros calificadores::Otros calificadores::/uso terapéutico
MDPI
Cancers;13(17)
https://doi.org/10.3390/cancers13174421
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
